Veraxa and Voyager Merge to Form Nasdaq Biotech for Cancer Pipeline
Details : The combined company will focus on the development of a comprehensive pipeline of next-generation cancer therapies, including novel ADC, VX-A902, and Bispecific TCE candidates.
Product Name : VX-A902
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
April 23, 2025
Medigene-BioNTech Collaboration Agreement Extended Beyond Initial Term
Details : The collaboration aims to advance T cell receptor immunotherapies against cancer
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 21, 2024
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
Details : A collaboration aims to develop mRNA-based cancer vaccines for high unmet needs in hematological and solid cancers, with MD Anderson leading phase 1/2 studies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 16, 2024
Details : Under the collaboration, Boehringer will use IBM’s foundation model technologies to discover novel candidate antibodies for the development of efficient therapeutics.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 29, 2023
Details : The agreement aims to combine Glycotope’s antibodies with Evotec’s immune cell engager platform for the development of next generation immune cell engaging bispecifics by Evotec.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 12, 2023
Details : The agreement aims to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies. LCB has worldwide exclusive rights to develop and commercialize the selected antibody as an ADC...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 16, 2023
Details : Under the collaboration, UCB’s proprietary mRNA-display platform, ExtremeDiversity™ and Ariceum’s expertise in radiopharmaceuticals & labelling technology will enable discovery of peptide-radioisotope conjugates as potential therapeutics for immune...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 05, 2023
Details : MDG2011, a T cell receptor engineered T cell (TCR-T) therapy targeting KRAS (Kirsten rat sarcoma viral oncogene homologue) G12V with HLA-A*11 and being developed in combination with the Company’s PD1-41BB costimulatory switch protein (CSP) technology.
Product Name : MDG2011
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 18, 2023
Evotec And Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
Details : Under the expanded collaboration, the companies will develop the pipeline of molecular glue degraders. The companies will leverage all of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $200.0 million
March 28, 2023
Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Details : Evotec has significantly scaled up its activities to develop compounds from BMS’s industry-leading library of cereblon E3 ligase modulators and continues to build a leading pipeline of novel molecular glue degraders, targeting high-value targets in the...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $200.0 million
March 16, 2023